Diagnostic, prognostic, and monitoring methods for solid tumor cancers
AssigneeOncoTracker, Inc.
InventorJames Richard BERENSON
Life of this patent
Estimating the term…
Abstract
The compositions and methods of the invention relate generally to detection of biomarkers for the diagnosis, prognosis, and monitoring of solid tumor cancers. In particular, the invention relates to compositions and methods for detection of B-cell maturation antigen (BCMA) for the diagnosis, prognosis, and monitoring of solid tumor type of cancers.
Claims25
A method of prognosis for a solid tumor type of cancer in a subject, comprising detecting an amount of BCMA polypeptide or a fragment thereof in a biological sample obtained from the subject.
(canceled)
A method of monitoring progression or response to treatment of solid tumor cancer, comprising detecting an amount of BCMA or a fragment thereof in a biological sample obtained from a subject diagnosed with the cancer at a time point following treatment.
(canceled)
(canceled)
14-15. (canceled)
The method of any of the preceding claims, wherein the BCMA polypeptide or a fragment thereof is detected using a detection system selected from the group consisting of enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (MA), enzyme immunoassay (EIA), fluorescence immunoassay (FIA), luminescence immunoassay (LIA), lateral flow assay (LFA), and strip assay.
A kit for monitoring progression or response to treatment of a solid tumor type of cancer in a subject, comprising a reagent suitable for determining levels of BCMA polypeptide or a fragment thereof in a biological sample obtained from the subject.
22-25. (canceled)
A method of treating breast cancer in a subject, comprising:
- a) detecting an amount of BCMA polypeptide or a fragment thereof in a biological sample obtained from the subject;
- and
- b) if the amount is greater than 15 ng/mL, administering an effective amount of letrozole, megestrol acetate, or letrozole and megestrol acetate.
Dependencies are inferred from the claim text.